Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02254239 · ClinicalTrials.gov registry record · Phase 1
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02254239: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT02254239 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02254239, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and the best dose of everolimus when given together with brentuximab vedotin in treating patients with Hodgkin lymphoma that has come back (relapsed) or is not responding to treatment (refractory). Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Brentuximab vedotin may interfere with the ability of cancer cells to grow and spread by binding to a protein on the surface of cancer cells and then releasing a cancer-killing substance to them. Giving everolimus together with brentuximab vedotin may be a better treatment for Hodgkin lymphoma.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Everolimus
- DRUG Brentuximab Vedotin
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-02-04 |
| Est. Completion | 2018-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02254239
The ClinicalTrials.gov registry entry for NCT02254239 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02254239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02254239 about?
NCT02254239 is a clinical study titled "Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma". This phase I trial studies the side effects and the best dose of everolimus when given together with brentuximab vedotin in treating patients with Hodgkin lymphoma that has come back (relapsed) or is not responding to treatment (refractory). Everolimus may stop the growth of cancer cells by blocking...
What is the current status of trial NCT02254239?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2016-02-04. Estimated completion is 2018-12-12.
What interventions are being tested in trial NCT02254239?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Everolimus (DRUG), Brentuximab Vedotin (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02254239?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.